[Changes of natural killer activity following local 60Co irradiation in intracranial tumor-bearing mice (author's transl)].
Changes of natural killer activity (NK activity) by local 60Co irradiation in intracranial tumor-bearing mice were studied by the method of 51Cr release assay. Local irradiation was administered 10 days after intracranial transplantation of 203-Glioma which had been originally induced by 20-methylcholanthrene in C 57 BL mice. Irradiation suppressed the growth of tumor and prolonged the mean survival time. The 50% survival time of untreated mice was about 2.5 weeks but that of mice treated by a single dose of 1000 rad and 1500 rad of irradiation was about 4.5 weeks and 6.5 weeks respectively. NK activity of spleen cells in these mice was serially examined. NK activity was gradually increased in mice treated by local irradiation, while it was gradually decreased in mice without treatment. On the other hand, NK activity remained unchanged in non-tumor-bearing control mice. Mice treated with 1000 rad and 1500 rad of irradiation showed 44.0% and 47.6% of % specific 51Cr release respectively 11 days after irradiation while normal mice showed 18.0%. The increased NK activity after local irradiation suggested that local irradiation might have enhanced the immunological defence mechanism against the tumor in the tumor-bearing hosts. Some characteristics of effector cells in this assay system were examined. The cytotoxicity of spleen cells was removed by the treatment of anti-BAT serum and complement but was not removed by the treatment of anti-Thy-1. 2 serum and complement. Since NK activity reflects the immunological resistance to tumors to some extent, it is felt important to clarify the significance of changes of NK activity in patients with brain tumors in relation to various treatments including surgery, radiotherapy, chemotherapy and immunotherapy in the next step.
D000818:Animals; D001932:Brain Neoplasms / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy; D003037:Cobalt Radioisotopes / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D005910:Glioma / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy; D007694:Killer Cells, Natural / Q000276:immunology*; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy; D011879:Radiotherapy Dosage
D003037:Cobalt Radioisotopes